In conclusion, our data, for the first time, not only provides direct evidence of mutant p53-induced chemoresistance by promoting cancer stemness in colorectal carcinoma but also highlights the potential targets of TCF21/CD44 against mutant p53-driven drug resistance. The gene discussed is TCF21; the disease is colorectal carcinoma.